New section in journal of translational medicine: patient-targeted molecular therapies
1 Chief Scientific Officer, Kite Pharma, Inc., 10924 Le Conte Avenue, Los Angeles, CA, 90024, USA
2 UCLA School of Dentistry, AAAS Fellow, Fulbright Specialist, CHS 63-090, 10833 Le Conte Avenue, Los Angeles, CA, 90095-1668, USA
3 Evidence-Based Decisions Practice-Based Research Network (EBD-PBRN.org), California, USA
Journal of Translational Medicine 2012, 10:92 doi:10.1186/1479-5876-10-92Published: 15 May 2012
This Editorial announces a new section in the Journal of Translational Medicine: Patient-Targeted Molecular Therapies. This section is dedicated to the dissemination of targeted molecular therapies in context of patient-centered outcomes research and evidence-based clinical decisions. The focus on patient-targeted molecular therapies – spanning small molecules and biomolecules alike – stems from the unprecedented growth in this arena. This is consonant with the overall objective of the Journal of Translational Medicine, which seeks out to expand firmly to other vast areas of medicine in the domain of translational science, viewed here as the transaction between translational research and translational effectiveness. As we inaugurate this new section in Journal of Translational Medicine, with its mission described in detail in this Editorial, we invite interested scientists to submit their work for publication.